MedPath

Testing the Effects of a Digital Intervention for Cannabis Harm Reduction - The Cann'App Randomized Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Cannabis Use
Harm Reduction
Registration Number
NCT07157540
Lead Sponsor
Jacques Gaume
Brief Summary

The goal of this clinical trial is to learn if a digital web application can prevent the risks related to cannabis use among adult regular cannabis users who are enrolled in a pilot trial for cannabis sales regulation conducted in Lausanne, Switzerland (i.e., Cann-L study) and have agreed that their data were used in other studies.

The main question it aims to answer is:

Do participants who have access to the intervention modules of the web application raise their use of protective behavorial strategies to lower cannabis-related risks?

Researchers will compare the intervention modules to a control module (i.e., information on cannabis-related risks and harm reduction) to see if the web application works to prevent the risks related to cannabis use. They will also compare intervention modules across each other to see whether one works better than another.

Participants will:

* Create a user account in the web application

* Access the web application using a laptop, tablet or smartphone

* Use the web application as they wish throughout the duration of the study

* Complete the regular Cann-L study questionnaires every six months, which will be used to measure their cannabis use and related risks.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
565
Inclusion Criteria
  • Eligible participants will be those included in the pilot trial of cannabis sales regulation in Lausanne, Switzerland (Cann-L study).

Inclusion criteria in Cann-L study are:

  • being adult (>18 years old),
  • having current cannabis use (i.e., use at least once a month over the last 6 months)
  • living in the city of Lausanne. To enter the study, they complete an entry assessment verifying their age and proof of residence, and confirming that they have current cannabis use.
Exclusion Criteria
  • Cann-L exclusion criteria comprise:
  • being younger than 18 years old,
  • being pregnant or breastfeeding,
  • having a health condition contraindicating the use of cannabis (e.g., severe psychiatric disorder).

The consent to participate in the Cann-L parent trial comprises an option to be contacted to participate in sub-studies, including studies on prevention measures. All participants having accepted to be so contacted will be proposed to participate in the present study.

Therefore, additional exclusion criteria for the present study include:

  • not providing informed consent to participate in sub-studies, including studies on prevention measures,
  • not providing informed consent to participate in the present study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
Frequency of Protective Behavioral Strategies for Marijuana Use as Measured by the PBSM-17 Short Form ScaleThis outcome will be assessed at 1- and 7-month follow-up.

This outcome will be measured using the Protective Behavioral Strategies for Marijuana Use (PBSM-17) Short Form scale, a self-reported 17-item questionnaire measuring the frequency of PBS for cannabis use on a 6-point Likert scale ranging from 1 (never) to 6 (always).

Secondary Outcome Measures
NameTimeMethod
Cannabis Use FrequencyThis outcome will be measured at 1- and 7-month follow-up.

Cannabis Use Frequency will be measured using a single item asking "During the past 30 days, on how many days did you use cannabis?"

Number of Hours High on a Typical DayThis outcome will be measured at 1- and 7-month follow-up.

The number of hours under influence will be measured using a single item asking "How many total hours were you high on a typical day when you had been using cannabis?"

Trial Locations

Locations (1)

Lausanne University Hospital

🇨🇭

Lausanne, Vaud Canton, Switzerland

Lausanne University Hospital
🇨🇭Lausanne, Vaud Canton, Switzerland
Jacques Gaume, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.